Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Finished Goods (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Finished Goods for 15 consecutive years, with $818000.0 as the latest value for Q1 2025.

  • Quarterly Finished Goods rose 1759.09% to $818000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $818000.0 through Mar 2025, up 1759.09% year-over-year, with the annual reading at $818000.0 for FY2024, 1759.09% up from the prior year.
  • Finished Goods hit $818000.0 in Q1 2025 for Guided Therapeutics, roughly flat from $818000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $818000.0 in Q4 2022 to a low of $32000.0 in Q1 2022.
  • Historically, Finished Goods has averaged $486588.2 across 5 years, with a median of $758000.0 in 2021.
  • Biggest five-year swings in Finished Goods: crashed 96.01% in 2021 and later soared 2456.25% in 2023.
  • Year by year, Finished Goods stood at $785000.0 in 2021, then rose by 4.2% to $818000.0 in 2022, then tumbled by 94.62% to $44000.0 in 2023, then soared by 1759.09% to $818000.0 in 2024, then changed by 0.0% to $818000.0 in 2025.
  • Business Quant data shows Finished Goods for GTHP at $818000.0 in Q1 2025, $818000.0 in Q4 2024, and $818000.0 in Q3 2024.